2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
R. Lor Randall, MD, FACS, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.
R. Lor Randall, MD, FACS, professor and The David Linn Endowed Chair for Orthopaedic Surgery, University of California Davis Health, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.
Research is looking into deep sequencing tumors to look for mutations that can be targeted with the cadre of biotargeting agents in primary bone and tissue sarcomas, explains Randall. Patients with these tumors eligible for chemotherapy will receive it in a conventional form. If they fail conventional chemotherapy, they will move on to more targeted agents, says Randall.
At the University of California Davis Health, when sarcoma is diagnosed based on biopsy, some of the original tumor is stored for precision medicine treatments, concludes Randall.
Related Content: